Resection without adjuvant therapy results in a low recurrence rate for patients with stage I (T1/2 N0) rectal cancer in the range of 4% to 16% at 5 years. There are limited data, however, regarding clinical or pathologic prognostic markers for recurrence in this population.
The aim of this study is to assess the clinical and pathologic factors associated with local recurrence and overall survival in patients with early-stage rectal cancer after resection.
This is a retrospective study.
This study was conducted at 2 tertiary care centers in Boston, Massachusetts.
From 2000 to 2008, 175 patients with stage I rectal cancer treated with local or total mesorectal excision without adjuvant therapy were identified.
Time to local recurrence after resection and overall survival were evaluated for all patients with complete follow-up data. Perioperative data were reviewed to identify staging method, preoperative CEA, type of surgery, tumor size, number of lymph nodes resected, histological grade, circumferential resection margin, perineural invasion, lymphovascular invasion, and tumor ulceration. Data were analyzed by using a Cox proportional hazards regression model.
Of the eligible cohort, 137 patients had complete follow-up data for analysis of time to local recurrence, and only 23 (16.8%) patients had local recurrence. Among these 23 patients, the median time to recurrence was 1.1 years (0.1–7.8). On multivariate analysis, male sex, current alcohol use, and tumor ulceration were associated with heightened risk of local recurrence. Of the original cohort, 173 patients had complete follow-up for overall survival analysis. Among these patients, the median overall survival was 12 years. On multivariable analysis, age at diagnosis >65 years and T2 pathologic stage were associated with decreased survival.
As in any retrospective study, there is a potential for selection bias. Several patients were excluded from the analysis due to inadequate follow-up data. These results from two academic medical centers with specialized colorectal surgeons may not be generally applicable. The relatively small number of events, ie, recurrences, suggest the findings should be validated in a larger study.
For patients with stage I rectal cancer treated with resection alone, these results provide important prognostic information and may help identify those who could benefit from additional therapy.
1Department of Radiation Oncology, Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts
2Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
3Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts
4Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts
5Department of Surgery, Brigham and Women’s Hospital, Boston, Massachusetts
6Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts
7Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts
Financial Disclosure: None reported.
Correspondence: Harvey J. Mamon, M.D., Ph.D., Brigham and Women’s Hospital, Department of Radiation Oncology, 75 Francis St, Boston, MA 02115. E-mail: email@example.com